Dynavax Technologies Corporation Stock Nasdaq
Equities
US2681581029
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 01 | Dynavax Technologies Corporation Announces Chief Financial Officer Changes | CI |
Feb. 23 | Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue | MT |
Financials (USD)
Sales 2024 * | 288M | Sales 2025 * | 347M | Capitalization | 1.48B |
---|---|---|---|---|---|
Net income 2024 * | 27M | Net income 2025 * | 51M | EV / Sales 2024 * | 3.15 x |
Net cash position 2024 * | 576M | Net cash position 2025 * | 711M | EV / Sales 2025 * | 2.23 x |
P/E ratio 2024 * |
49.3
x | P/E ratio 2025 * |
31.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.69% |
Latest transcript on Dynavax Technologies Corporation
Managers | Title | Age | Since |
---|---|---|---|
Ryan Spencer
CEO | Chief Executive Officer | 46 | 04-12-31 |
David Novack
PSD | President | 62 | 13-03-24 |
Patricia Novy
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Francis Cano
BRD | Director/Board Member | 79 | 09-11-02 |
Peggy Phillips
BRD | Director/Board Member | 70 | 06-07-31 |
Dan Kisner
BRD | Director/Board Member | 77 | 10-07-21 |
1st Jan change | Capi. | |
---|---|---|
-2.63% | 102B | |
+1.62% | 96.29B | |
+2.71% | 22.18B | |
-16.67% | 21.2B | |
-8.75% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |